Ensuring Informed CML Care from Diagnosis Onward

Opinion
Video

Experts on chronic myeloid leukemia delve into the important role of informed shared decision-making in the optimal treatment of patients with CML.

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following:

  • As patients progress through their CML journey, how does the focus of shared decision-making evolve between the patient, caregiver, and healthcare team? What are some of the key challenges or changes you've observed in the patient, physician, and caregiver role over time?
    • What advice would you direct to patients and caregivers in navigating these changes?
Recent Videos
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content